BIOMAT Database Logo BIOMAT Database Logo

[Monitoring therapy with L-asparaginase. Model of drug-induced antithrombin III deficiency]. 1985

K Ranft, and E Hammer, and W Imhof, and P Prager

UI MeSH Term Description Entries
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001215 Asparaginase A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1. Asparaginase II,Asparaginase medac,Asparagine Deaminase,Colaspase,Crasnitin,Elspar,Erwinase,Kidrolase,Leunase,Paronal,Deaminase, Asparagine,medac, Asparaginase
D013927 Thrombosis Formation and development of a thrombus or blood clot in BLOOD VESSELS. Atherothrombosis,Thrombus,Blood Clot,Blood Clots,Thromboses
D020152 Antithrombin III Deficiency An absence or reduced level of Antithrombin III leading to an increased risk for thrombosis. Antithrombin 3 Deficiency,Congenital Antithrombin III Deficiency,Deficiency, Antithrombin III,Hereditary Antithrombin Deficiency,Antithrombin 3 Deficiencies,Antithrombin III Deficiencies,Deficiencies, Antithrombin 3,Deficiencies, Antithrombin III,Deficiency, Antithrombin 3

Related Publications

K Ranft, and E Hammer, and W Imhof, and P Prager
Antithrombin III deficiency during asparaginase therapy.
March 1980, Lancet (London, England),
K Ranft, and E Hammer, and W Imhof, and P Prager
Antithrombin III deficiency during asparaginase therapy.
March 1980, Lancet (London, England),
K Ranft, and E Hammer, and W Imhof, and P Prager
[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)].
November 1981, Archives francaises de pediatrie,
K Ranft, and E Hammer, and W Imhof, and P Prager
Reduced antithrombin III levels during L-asparaginase therapy.
January 1980, Medical and pediatric oncology,
K Ranft, and E Hammer, and W Imhof, and P Prager
L-asparaginase induced antithrombin III deficiency: evidence against the production of a hypercoagulable state.
February 1983, Thrombosis research,
K Ranft, and E Hammer, and W Imhof, and P Prager
L-asparaginase, antithrombin III, and thrombosis.
May 1980, Lancet (London, England),
K Ranft, and E Hammer, and W Imhof, and P Prager
Antithrombin III concentrations associated with L-asparaginase administration.
January 1992, Veterinary clinical pathology,
K Ranft, and E Hammer, and W Imhof, and P Prager
Fatal pulmonary embolism and antithrombin III deficiency in adult lymphoblastic leukaemia during L-asparaginase therapy.
January 1983, Acta haematologica,
K Ranft, and E Hammer, and W Imhof, and P Prager
L-asparaginase effect on antithrombin-III levels.
January 1979, Medical and pediatric oncology,
K Ranft, and E Hammer, and W Imhof, and P Prager
L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.
July 2006, The American journal of pathology,
Copied contents to your clipboard!